PPD Announces Fourth Quarter and Full-Year 2009 Earnings Release, Webcast and Conference Call

25 Jan. 2010


WILMINGTON, N.C. (January 25, 2010) - PPD, Inc. (Nasdaq: PPDI) will release its fourth quarter and full-year 2009 financial results on Monday, February 8, 2010, after the market closes. The earnings release will be available on the PPD Web site at

On Tuesday, February 9, 2010, at 9:30 a.m. ET, PPD will conduct a live conference call and audio webcast to discuss financial results and the overall business environment. A Q&A session will follow. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:

Participant dial-in: +1 877 644 0692 (U.S./Canada)
+1 973 200 3387 (International)
Conference ID: 43391595

All interested parties can access the webcast through the Presentations & Events link in the Investors section of the PPD Web site at The webcast will be archived shortly after the call for on-demand replay.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the spin-off and its anticipated benefits for PPD and Furiex Pharmaceuticals, are forward-looking statements that involve a number of risks and uncertainties. Although PPD and Furiex attempt to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: Furiex's lack of history as, and challenges operating as, an independent public company; anticipated losses and the potential need for Furiex to raise additional capital; its reliance on a limited number of products and product candidates; the ability to attract and retain key personnel; risks associated with the development and commercialization of drugs, including the ability to successfully launch and market a drug; the risk that safety issues might arise in the post-approval market; reliance on collaborators; competition in the market; rapid technological advances that make our products less competitive; and the other risk factors set forth from time to time in the Furiex Form 10 and other SEC filings, and in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
Tel: +1 919 456 4425

Holly Devine Manager, Corporate Communications
Tel: +1 919 456 6389

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2019 Pharmaceutical Product Development, LLC. All rights reserved.